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Abstract: Retinal vein occlusions (RVOs) constitute the second most common cause of 
retinal vascular disease after diabetic retinopathy, with a prevalence of between 1% and 2% 
in persons older than 40 years of age. Despite the existence of numerous potential therapeutic 
options, none is entirely satisfactory, and many patients with RVO suffer irreversible visual 
loss. Fortunately however, the recent introduction of antivascular endothelial growth factor 
(VEGF) agents, such as ranibizumab (Lucentis®, Genentech, South San Francisco, CA) and 
bevacizumab (Avastin®, Genentech), offers a potentially new treatment approach for clinicians 
managing this disorder. The results of the BRAVO and CRUISE trials have provided the first 
definitive evidence for the efficacy and safety of ranibizumab in the treatment of RVO. As a 
result, ranibizumab has recently been approved by the US Food and Drug Administration for 
the treatment of   RVO-associated macular edema. In this review, we provide a critical evaluation 
of clinical trial data for the safety and efficacy of ranibizumab, and address unresolved issues 
in the management of this disorder.
Keywords: ranibizumab, retinal vein occlusion, vascular endothelial growth factor, 
macular edema
Introduction
The retinal circulation is ordinarily an end-artery system that does not communicate 
with the blood vessels of the choroid and ciliary body – blockage of the retinal 
venous circulation thus leads to significant retinal damage with accompanying visual 
loss.1 As such, retinal vein occlusions (RVOs) constitute the second most common 
cause of retinal vascular disease after diabetic retinopathy, with a prevalence of 
between 1% and 2% in persons older than 40 years of age.2–4 Despite the existence 
of numerous potential therapeutic options, none is entirely satisfactory, and many 
patients with RVO suffer irreversible visual loss.5 Fortunately however, the recent 
introduction of antivascular endothelial growth factor (VEGF) agents, such as 
ranibizumab (Lucentis®, Genentech, South San Francisco, CA) and bevacizumab 
(Avastin®, Genentech), offers a potentially new treatment approach for clinicians 
managing this disorder.6
In this review, we begin by providing an overview of RVO pathophysiology and 
describing existing treatment options for associated macular edema; we continue by 
highlighting the role of VEGF in RVO-associated macular edema, before describing 
the pharmacology of ranibizumab. We conclude with a critical evaluation of clinical 
trial data for the safety and efficacy of ranibizumab in this disorder.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Pathophysiology of retinal  
venous occlusion
RVOs typically occur as a result of arteriosclerosis and, 
hence, systemic cardiovascular risk factors (eg, hypertension, 
hyperlipidemia, diabetes mellitus) play a key pathogenic 
role.7,8 In patients with arteriolosclerosis, thickening and 
hardening of the retinal arterial walls may lead to retinal 
venous narrowing and stasis, with resultant thrombosis (the 
distribution of the retinal venous circulation mirrors that 
of the retinal arterial circulation and, at crossing-points, 
arteries and veins share a common adventitial sheath). In 
younger patients, hypercoagulability may also be a factor.8 
Occlusion of the retinal vein by thrombosis then leads to 
elevation of venous and intracapillary pressure, with slow-
ing of arterial blood flow – the combination of these factors 
leads to extravasation of serous fluid and hemorrhage, as well 
as varying amounts of capillary endothelial damage. The 
subsequent marked increase in interstitial fluid and protein 
leads to an increased interstitial pressure, which can act as 
an impediment to capillary perfusion and result in ischemia 
(the role of VEGF and other growth factors in this process 
is discussed in a later section).1,9
Visual loss in RVO occurs through a varying combina-
tion of three distinct mechanisms.1,9 Firstly, serous exudation 
distal to the point of obstruction may result in macular edema; 
when the associated damage to the vascular architecture is 
severe, such edema may become prolonged or permanent 
with attendant degenerative changes (macular holes, epireti-
nal membranes etc). Secondly, retinal hemorrhages may 
be seen in the area drained by the retinal vein distal to its 
obstruction; in severe cases, dissection of blood beneath the 
retina may lead to retinal pigment epithelium (RPE) atrophy 
and/or scarring, often in a subfoveal location. Finally, venous 
obstruction may be accompanied by ischemic damage to 
the retina, with extensive loss of the capillary bed and post-
ischemic atrophic changes. When sufficient retinal ischemia 
is present, pathologic retinal neovascularization may ensue, 
resulting in vitreous hemorrhage and/or tractional retinal 
detachment, while iris neovascularization may culminate in 
“neovascular” glaucoma.10,11
Current treatment of retinal  
venous occlusion
RVOs are typically classified according to whether the 
obstruction occurs in the central retinal vein (central retinal 
vein occlusion [CRVO]) or one of its branches (branch retinal 
vein occlusion [BRVO]). This distinction is important as 
there are significant differences in the clinical features, and 
response to treatment, of each entity.12,13 For both CRVO 
and BRVO, the development of pathologic neovasculariza-
tion is typically treated with scatter laser photocoagulation 
to the peripheral areas of nonperfused retina. However, the 
treatment of visual loss resulting from macular edema is 
more complex.
Patients with macular edema as a result of BRVO 
typically present with moderately reduced visual acuity and 
even without intervention, the visual status of such patients 
frequently improves over time.11 For those BRVO patients 
with persistent macular edema, and visual acuity of 20/40 
or worse, grid laser photocoagulation to the area of capillary 
leakage within the macula – and outside the foveal avascular 
zone – may be of benefit. In the Branch Vein Occlusion 
Study (BVOS), eyes treated with grid laser photocoagula-
tion were almost twice as likely as untreated eyes to gain 
2 additional lines of visual acuity at 3 years (65% versus 
37%).14 However, in some patients, poor vision persisted 
despite treatment: in 40% of treated eyes, visual acuity was 
worse than 20/40 at 3 years, while in 12% of such eyes it 
remained below 20/200.
In comparison with BRVO, patients with   CRVO-associated 
macular edema often present with more significantly reduced 
vision, which often deteriorates further with time, regardless 
of intervention.10 However, the visual prognosis in such 
patients very much depends on the perfusion status of the 
retina at the time of occlusion.1,15 Patients with “nonischemic” 
(or “perfused”) CRVO often have relatively benign disease, 
with resolution of macular edema in approximately 30% of 
eyes over time (and pathologic neovascularization occur-
ring only rarely).10 However, in patients with “ischemic” 
(or “nonperfused”) CRVOs, there is little chance of visual 
improvement, and the risk of pathologic neovascularization 
is high (neovascular glaucoma develops in approximately 
25% of these eyes).10 Unlike BRVO, the available evidence 
suggests that grid laser photocoagulation of macular edema 
in patients with CRVO is of no visual benefit.12 In the Central 
Vein Occlusion Study (CVOS), patients with macular edema 
caused by CRVO, and visual acuity of 20/50 or worse, had no 
significant improvement in vision after 3 years of treatment 
with grid laser therapy (although fluorescein angiographic 
leakage was reduced).16
More recently, the role of intraocular corticosteroids 
in the treatment of RVO-associated macular edema has 
been extensively investigated. In addition to their potent 
anti-inflammatory effect, corticosteroids are known to Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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reduce vascular permeability.17 In the Standard Care versus 
Corticosteroid for Retinal Vein Occlusion (SCORE) study, 
similar outcomes were achieved when BRVO was treated 
with either grid laser photocoagulation or preservative-free 
intravitreal triamcinolone; however, adverse events, such 
as increased intraocular pressure or cataract progression, 
were higher in those receiving triamcinolone.18 In contrast, 
for patients with macular edema secondary to nonischemic 
CRVO, treatment with intravitreal triamcinolone led to supe-
rior outcomes than observation alone. Of subjects receiving 
triamcinolone 1 mg and 4 mg, 27% and 26%, respectively 
achieved a gain in visual acuity of 15 or more letters, versus 
only 7% of controls.19
While it is clear that grid laser photocoagulation is helpful 
for the treatment of BRVO, and that intravitreal triamcino-
lone is superior to observation alone for the treatment of some 
patients with CRVO, the limitations of both approaches are 
readily apparent. However, the isolation of VEGF in 1989, 
and the increasing awareness of its role in chorioretinal 
vascular diseases, has offered new opportunities to address 
these shortcomings.19
vascular endothelial growth factor  
and ranibizumab
In the past 20 years, significant progress has been made in 
our understanding of angiogenesis, the process by which 
new blood vessel formation occurs in adults.20 Angiogenic 
processes are initiated by an angiogenic stimulus, most com-
monly hypoxia, which leads to the upregulation of growth 
factor expression. Growth factor production, in turn, leads 
to vasodilatation and increases in vascular permeability, and 
ultimately to formation of a complex vascular network. Each 
step of the angiogenic sequence is controlled by a delicate 
balance between pro- and anti-angiogenic growth factors, 
the most important of which is VEGF-A (other important 
factors include fibroblast growth factor, platelet-derived 
growth factor, and erythropoietin).21
VEGF-A, first isolated in 1989 by Ferrara et al, is a gly-
coprotein produced by cells in response to hypoxia – cells 
deficient in oxygen produce a transcription factor, hypoxia 
inducible factor, that stimulates its production and release.22,23 
Circulating extracellular VEGF-A then binds to receptors on 
endothelial cells, leading to increased vascular permeability 
and proliferation of the endothelial cells. VEGF-A is the 
prototype member of a gene family (a group of genes with 
shared sequences and with similar biochemical functions) 
that also includes placental growth factor (PIGF), VEGF-B, 
VEGF-C, VEGF-D, and VEGF-E (prior to the discovery 
of others, VEGF-A was known simply as VEGF and the 
terms are used interchangeably in this review). VEGF-A has 
4 major isoforms – different forms produced by alternative 
gene splicing. Isoforms 165 and 121 are freely diffusible 
outside the cell, whereas isoforms 189 and 206 are almost 
completely sequestered in the extracellular matrix.
For both CRVO and BRVO, the extent of associated 
retinal ischemia is dependent on the severity and location 
of the obstruction (although CRVO is typically classified 
as ischemic or nonischemic, a degree of retinal ischemia 
is   present in both subtypes).1,24 As VEGF is produced in 
response to hypoxia, it is not surprising that increased 
levels of this growth factor have been found in the ocular 
fluids of patients with RVO. In fact, intravitreal levels of 
VEGF in CRVO are the highest of those measured among 
all retinal vascular disease.25 Upregulation of retinal VEGF 
mRNA expression has also been demonstrated in patients 
with RVO;26 and correlations have been detected between 
aqueous concentrations of VEGF and the onset of iris 
  neovascularization.27   Furthermore, in primate models, almost 
all the features of CRVO can be replicated by intravitreal 
injection of VEGF.28 Thus, for patients with RVO, strategies 
aimed at VEGF inhibition represent an attractive therapeutic 
approach, although, for RVO-associated macular edema, the 
relative contribution of hydrodynamic changes secondary 
to obstruction versus growth factor upregulation remains 
unclear. Furthermore, VEGF may be critical to the formation 
of retinal collateral circulations and the establishment of a 
new retinal blood flow equilibrium. Currently, one of the 
most effective methods for the inhibition of VEGF is through 
the intravitreal administration of ranibizumab.
Ranibizumab is an antibody fragment that binds and 
inhibits all isoforms of VEGF-A.29 It is a chimeric molecule, 
consisting of an antigen-binding murine component, and a 
nonbinding human component that serves to make it less anti-
genic (in Greek mythology, the chimera was a monster with a 
lion’s head, a goat’s body, and a serpent’s tail). Ranibizumab 
was developed by alteration of trastuzumab which is also 
similar to bevacizumab (Avastin), a humanized version of a 
murine full-length monoclonal antibody first derived in 1996, 
and used in the treatment of colorectal carcinoma.22 The need 
for herceptin alteration was driven by preclinical studies sug-
gesting that a full-size antibody would be unable to penetrate 
the retina (in apparent conflict with these findings, Shahar et al 
recently reported that, in rabbit eyes, intravitreal injection of 
bevacizumab resulted in penetration throughout the retina, but Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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not within the RPE or choroid).30,31   Substitution of targeted 
amino acids was also performed in a bid to maximize the 
binding affinity of ranibizumab for VEGF, in the hope that 
this change would lead to improved outcomes (the VEGF 
binding affinity of ranibizumab is approximately 100 times 
that of bevacizumab).22 In 2006, ranibizumab was licensed by 
the US Food and Drug Administration (FDA) for use in the 
United States to treat neovascular age-related macular degen-
eration (AMD) (www.gene.com/gene/products/  information/
tgr/lucentis; accessed February 18th, 2011).
Use of ranibizumab in retinal vein 
occlusions
The potential of anti-angiogenic therapy – pegaptanib, beva-
cizumab, and ranibizumab – for the treatment of RVO was 
recognized at an early stage; in fact, the first use of bevaci-
zumab in CRVO was described prior to the FDA clearance 
of ranibizumab for neovascular AMD.32 More recently, a 
number of prospective studies have evaluated the role of 
ranibizumab in this context.33
initial prospective ranibizumab studies
In a small, single-center trial, Pieramici et al evaluated 
the role of intravitreal ranibizumab for the treatment of 
CRVO-associated macular edema (www.clinicaltrials.
govNCT00406796).34 In this study, 10 patients with perfused 
CRVO were randomized to receive either 0.3 mg (n = 5) or 
0.5 mg (n = 5) of ranibizumab. Subjects initially received 
ranibizumab at baseline, and then monthly for 2 additional 
doses, with subsequent quarterly retreatment as required 
for recurrent or persistent edema. After the initial loading 
phase, 40% of patients gained 15 or more letters of visual 
acuity, with a mean increase of 12 letters, and a reduction in 
optical coherence tomography (OCT)-derived central retinal 
thickness (CRT) of 272 µm. After 9 months however, these 
benefits had lessened – 30% of participants gained 15 or more 
letters of visual acuity, with a mean increase of only one letter, 
and a reduction in CRT of 119 µm. As a result of these find-
ings, the trial protocol was amended in its second year, with 
subjects being reviewed monthly and receiving ranibizumab 
retreatment (0.5 mg) as required.35 In addition, a second 
cohort of patients (n = 10) was recruited and, following a 
similar loading phase, also received monthly, as required, 
ranibizumab retreatment. In the first cohort of patients, 
initial gains in visual acuity were lost with quarterly retreat-
ment – these gains returned when the potential for monthly 
retreatment was provided in the second year. For the second 
cohort, the visual gains attained during the loading phase 
were maintained until the conclusion of the study at 2 years. 
A number of anatomic parameters other than CRT were also 
evaluated: for 19 of the 20 participants, ranibizumab resulted 
in reductions in intraretinal hemorrhage, optic nerve swelling, 
and/or venous diameter. Finally, no serious ocular adverse 
events were reported, although, over the 2-year period, one 
subject suffered from a myocardial infarction and one from 
a cerebrovascular event.
In a further small, single-center trial (www.clinicaltrials.
gov NCT00407355), Campochiaro et al evaluated the role 
of ranibizumab in the treatment of macular edema in both 
CRVO (n = 20) and BRVO (n = 20).36 Again, participants 
were randomized to 0.3 or 0.5 mg of ranibizumab, with a 
loading phase of three injections. For the remainder of the 
first year, attempts were then made to wean subjects off 
ranibizumab (in the hope that collateral formation and/or 
venous recanalization would render prolonged treatment 
unnecessary). In the second year, however, subjects were 
seen every 2 months, and received ranibizumab (0.5 mg) as 
required for recurrent edema.37 Seventeen of 20 patients with 
BRVO completed 2 years of follow-up in this study, with 
a mean visual acuity increase of 17.8 letters (18% gained 6 
or more lines of visual acuity, 59% gained 3 or more lines, 
and 76% gained 2 or more lines). On OCT, CRT decreased 
from an average of 481.5 µm at baseline, to 245.8 µm at 
month 24, with patients requiring an average of 2 ranibi-
zumab retreatments in their second year. Fourteen of 20 
patients with CRVO completed 2 years of follow-up, with a 
mean visual acuity increase of 8.5 letters – versus 12 letters 
following the loading phase (14% gained 6 or more lines of 
visual acuity, 21% gained 3 or more lines, and 43% gained 
2 or more lines). On OCT, CRT decreased from an average 
of 533 µm at baseline, to 338 µm at month 24, with patients 
requiring an average of 3.5 injections in their second year. 
Additional analyses revealed that when the occlusion was 
present for more than a year prior to enrollment, or that 360-
degree nonperfusion of the parafoveal capillaries was present, 
less favorable visual outcomes were achieved.
Spaide et al have also reported the outcomes of a small, 
prospective trial of ranibizumab for treatment of CRVO (FDA 
Investigator Investigational New Drug number 100,240).38 
In this study, patients with CRVO-associated macular 
edema (n = 20: visual acuity between 20/40 and 20/200, 
CRT . 250 µm) received ranibizumab at baseline (0.5 mg) 
and then monthly for 2 additional doses. Patients were then 
reviewed monthly and received ranibizumab retreatment Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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when either macular edema, or new intraretinal hemorrhage, 
were detected. Of note, many of the patients enrolled in this 
study were not treatment-naïve: 5 had previously received 
intravitreal triamcinolone, while 11 had received intravitreal 
bevacizumab. At 12 months of follow-up, participants had 
received an average of 8.5 ranibizumab injections – these 
injections led to an improvement in mean visual acuity of 
18.5 letters, accompanied by a mean reduction in CRT of 
388.6 µm (although reductions in CRT were not correlated 
with improvements in visual acuity). In one patient, with a 
history of transient ischemic attack, a cerebrovascular event 
was reported; in another, vitreomacular traction developed, 
although the patient’s visual acuity remained improved rela-
tive to baseline.
The results of these initial, small, prospective studies have 
provided much valuable information for clinical practice and 
for the design of clinical trials; moreover, a number of sub-
sequent case series have corroborated their findings.39–42 For 
patients with RVO-associated macular edema,   ranibizumab 
therapy appears to provide significant visual benefits, with 
visual acuity gains comparable to, or potentially better than, 
other therapeutic approaches. In addition to functional gain, 
ranibizumab therapy results in significant reductions in 
excess retinal thickening as determined using OCT (although 
the exact nature of the relationship between anatomic gains 
and visual benefit remains unclear). For patients with CRVO, 
it appears that frequent – potentially monthly – monitoring 
may be required for extended periods, coupled with aggres-
sive retreatment of recurrent or persistent edema; for patients 
with BRVO, less frequent retreatment may be sufficient. 
While these results are promising, the nature of the studies 
precludes the drawing of firm conclusions regarding efficacy, 
and comparison with other therapies should be made with 
caution. Furthermore, the small numbers enrolled in these 
studies do not allow conclusions to be drawn regarding the 
safety of this approach. Fortunately, a number of large, ran-
domized, controlled, multi-center, clinical trials have been 
undertaken – both for BRVO and for CRVO – and their initial 
findings have been reported.
CRUiSe
Treatment of CRVO-associated macular edema was evalu-
ated in the phase III, Central Retinal Vein OcclUsIon Study: 
Evaluation of Efficacy and Safety trial (CRUISE – www.
clinicaltrials.gov NCT00485836).43 The CRUISE trial 
was a 6-month, multi-center, randomized, sham injection-
controlled study, with an additional 6 months of follow-up 
(total 12 months). The study included a 6-month treatment 
period, during which subjects received monthly intraocular 
injections of 0.3 mg or 0.5 mg ranibizumab, or sham injec-
tions; and a 6-month observation period, during which all 
patients could receive monthly ranibizumab retreatment if 
they met prespecified functional and anatomic criteria (visual 
acuity #20/40 or OCT-derived CRT $ 250 µm). Study visits, 
including OCT imaging, were also carried out 7 days after 
baseline treatment.
392 subjects with CRVO-associated macular edema were 
enrolled.43 Key inclusion criteria included: CRVO-associated 
macular edema diagnosed within 12 months of study initia-
tion, best-corrected visual acuity between 20/40 and 20/320, 
and OCT-derived CRT $ 250 µm (mean value obtained from 
2 measurements using Stratus OCT [Carl Zeiss Meditec, 
Dublin, CA]). Of note, the presence of an “obvious and 
unequivocal” afferent pupillary defect, or previous RVO, were 
among the exclusion criteria. The primary efficacy outcome 
measure was mean change from baseline visual acuity at 
month 6. Secondary efficacy outcome measures included 
percentage of patients who gained $15 letters from baseline 
visual acuity at month 6. Additional, exploratory, efficacy 
outcomes included mean change from baseline NEI VFQ-25 
(National Eye Institute Visual Functioning Questionnaire-25) 
composite score at month 6, and percentage of patients with 
visual acuity $20/40 at month 6. Safety outcomes included 
the incidence and severity of ocular and nonocular adverse 
events and serious adverse events.
Mean change from baseline visual acuity at month 
6 – the primary endpoint of the study – was +12.7 letters 
and +14.9 letters in the 0.3 mg and 0.5 mg ranibizumab 
groups respectively, and +0.8 letters in the sham group 
(P , 0.0001 for each ranibizumab group versus sham).43 
The percentage of patients who gained $15 letters in visual 
acuity at month 6 was 46.2% (0.3 mg) and 47.7% (0.5 mg) 
in the ranibizumab groups, and 16.9% in the sham group 
(P , 0.0001 for each ranibizumab group versus sham). At 
month 6, significantly more ranibizumab-treated patients 
(0.3 mg = 43.9%; 0.5 mg = 46.9%) had BCVA of $ 20/40 
compared with sham patients (20.8%; P , 0.0001 for each 
ranibizumab group versus sham), and OCT-derived CRT had 
decreased by a mean of 434 µm (0.3 mg) and 452 µm (0.5 mg) 
in the ranibizumab groups and 168 µm in the sham group 
(P , 0.0001 for each ranibizumab group versus sham). An 
improvement from baseline in the mean NEI VFQ-25 score 
was observed as early as month one in ranibizumab-treated 
patients. At month 6, the mean change from baseline score Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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was 7.1, 6.2, and 2.8 points in the 0.3 mg, 0.5 mg, and sham 
groups respectively (P , 0.05 for each ranibizumab group 
versus sham). Finally, the safety profile was consistent with 
previous phase III clinical trials of ranibizumab, and no new 
safety events were identified in patients with CRVO.
Significant  reductions  in  macular  edema  were 
seen in both patient groups receiving ranibizumab at 
study visit Day 7; these changes were accompanied by 
  significant visual   improvements.43 Thus, the majority of 
CRVO-associated macular edema appears to be VEGF medi-
ated, rather than occurring secondary to increased venous 
pressure. The findings of the CRUISE trial also suggest 
that retinal ischemia is present even in patients traditionally 
described as having nonischemic CRVO. Of further note, 
patients in the CRUISE sham injection arm demonstrated 
similar outcomes to those of the natural history cohort in 
the CVOS study; but these outcomes differed from those 
described in the SCORE study.16,19,43 Although the baseline 
visual acuity of CRUISE patients was slightly worse than that 
of SCORE CRVO patients (48.3 letters versus 51.0 letters 
respectively), CRUISE had fewer patients with large areas 
of capillary nonperfusion. This difference may have come 
about due to the exclusion of patients with an afferent pupil-
lary defect from the CRUISE study, thus eliminating those 
patients with extensive capillary nonperfusion.
BRAvO
Treatment of BRVO-associated macular edema was evaluated 
in the phase III, BRAnch Retinal Vein Occlusion: Evaluation 
of Efficacy and Safety trial (BRAVO – www.clinicaltrials.
gov NCT00486018).44 The BRAVO trial was a 6-month, 
multicenter, randomized, sham injection-controlled study, 
with an additional 6 months of follow-up (total 12 months). 
The study included a 6-month treatment period, during which 
subjects received monthly intraocular injections of 0.3 mg or 
0.5 mg ranibizumab, or sham injections; and a 6-month obser-
vation period, during which all patients could receive monthly 
ranibizumab retreatment if they met prespecified functional 
and anatomic criteria (visual acuity #20/40 or OCT-derived 
CRT $ 250 µm). Study visits, including OCT imaging, were 
also carried out 7 days after baseline treatment.
392 subjects with BRVO-associated macular edema 
were enrolled.44 Key inclusion criteria included: BRVO-
associated macular edema diagnosed within 12 months 
of study initiation, best-corrected visual acuity between 
20/40 and 20/400, and OCT-derived CRT $ 250 µm (mean 
value obtained from 2 measurements using Stratus OCT). 
The primary efficacy outcome measure was mean change 
from baseline visual acuity at month 6. Secondary efficacy 
outcome measures included percentage of patients who 
gained $15 letters from baseline visual acuity at month 6. 
Additional, exploratory, efficacy outcomes included mean 
change from baseline NEI VFQ-25 composite score at 
month 6, and percentage of patients with visual acuity $20/40 
at month 6. Safety outcomes included the incidence and 
severity of ocular and nonocular adverse events and serious 
adverse events.
Mean change from baseline visual acuity at month 
6 – the primary endpoint of the study – was +16.6 and +18.3 
letters in the 0.3 mg and 0.5 mg ranibizumab groups respec-
tively, and +7.3 letters in the sham group (P , 0.0001 for 
each ranibizumab group versus sham).44 The percentage of 
patients who gained $15 letters in visual acuity at month 6 
was 55.2% (0.3 mg) and 61.1% (0.5 mg) in the ranibizumab 
groups, and 28.8% in the sham group (P , 0.0001 for each 
ranibizumab group versus sham). At month 6, significantly 
more ranibizumab-treated patients (0.3 mg, 67.9%; 0.5 mg, 
64.9%) had BCVA of $20/40 compared with sham patients 
(41.7%; P , 0.0001 for each ranibizumab group versus 
sham), and OCT-derived CRT had decreased by a mean of 
337 µm (0.3 mg) and 345 µm (0.5 mg) in the ranibizumab 
groups and 158 µm in the sham group (P , 0.0001 for each 
ranibizumab group versus sham). An improvement from 
baseline in the mean NEI VFQ-25 score was observed as 
early as month one in ranibizumab-treated patients. At month 
6, the mean change from baseline score was 9.3, 10.4, and 5.4 
points in the 0.3 mg, 0.5 mg, and sham groups respectively 
(P , 0.05 for each ranibizumab group versus sham). Finally, 
the safety profile was consistent with previous phase III 
clinical trials of ranibizumab, and no new safety events were 
identified in patients with CRVO.
As the efficacy of grid laser photocoagulation for the 
treatment of BRVO-associated macular edema had already 
been demonstrated in the BVOS,14 BRAVO participants 
were eligible for grid laser 3 months after study entry if 
they had not shown evidence of substantial visual or ana-
tomic improvement from baseline (providing there was 
sufficient clearing of retinal hemorrhages).44 As a result, in 
the BRAVO study, 54.5% of patients receiving sham injec-
tions received rescue laser therapy, whereas only 18.7% 
and 19.8% of the 0.3 mg and 0.5 mg ranibizumab groups 
required the same. Therefore, the modest improvements 
seen in the sham group may be attributable, at least in part, 
to the rescue therapy.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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ROCC
In addition to CRUISE and BRAVO, the smaller ROCC 
study (randomized study comparing ranibizumab to sham 
in patients with macular edema secondary to central Retinal 
vein OCClusion) has also employed a randomized, sham-
controlled, multi-center, methodology to evaluate the efficacy 
of ranibizumab in RVO.45 In this 6-month trial, 32 patients 
with CRVO-associated macular edema were randomized to 
receive monthly intravitreal ranibizumab (0.5 mg) or sham 
injections for 3 consecutive months, with monthly retreatment 
as required. Twenty-nine patients completed the study and, at 
6 months, the mean change in visual acuity was +12 letters 
for the ranibizumab group, compared with −1 letter for the 
sham injection group (P = 0.067). The mean reduction in 
OCT-derived CRT was 304 µm for the ranibizumab group, 
compared with 151 µm for the sham group.
Conclusions and future directions
FDA approval
The results of the BRAVO and CRUISE studies provided 
the first definitive evidence for the efficacy and safety of 
ranibizumab in the treatment of RVO.43,44 Consequently, fol-
lowing a priority review, ranibizumab was approved by the 
FDA for macular edema following RVO on June 22, 2010 
(www.gene.com/gene/products/information/tgr/lucentis; 
accessed February 18th, 2011). In essence, the BRAVO and 
CRUISE studies demonstrated that just under two-thirds 
(61%) of patients with BRVO-associated macular edema, 
and just under half (48%) of patients with CRVO-associated 
macular edema, attained significant visual improvement (ie, 
15 or more letters) when treated with intravitreal ranibizumab 
(0.5 mg). By comparison, in the MARINA and ANCHOR 
studies of neovascular AMD, approximately one-third of 
participants demonstrated similar visual improvement (33.8 
and 40.3% respectively).46,47
Unanswered questions
Despite the unprecedented findings of the BRAVO and 
CRUISE trials, a number of significant questions remain 
unanswered.43,44 In particular, the role of ranibizumab in 
treatment of patients with visual acuities better than 20/40 
was not addressed by these studies. This is a significant 
issue given that, in the natural history arm of CVOS, 29% 
of subjects presented with a visual acuity $20/40.16 Fur-
thermore, the efficacy of ranibizumab in the treatment of 
patients with severely reduced visual acuity and, potentially, 
advanced macular ischemia, was not evaluated (the presence 
of an afferent pupillary defect was an exclusion criterion for 
both CRUISE and BRAVO, thus eliminating many subjects 
with ischemic CRVO).43,44 Ranibizumab may be of benefit 
in treating such patients. Caution is required, however, as 
VEGF has also been shown to have neuroprotective proper-
ties; such qualities may acquire increased significance in 
the context of significant capillary nonperfusion.48 Campo-
chiaro et al have also provided some evidence that complete 
disruption of the foveal avascular zone may correlate with 
poor visual outcomes.36 Therefore, as with neovascular 
AMD and other macular disorders, future, cellular-based 
therapies may acquire an important role in certain disease 
phenotypes.49
Another unanswered question is how long therapy may be 
deferred. It is well known from various vein occlusion trials 
that some patients can experience a spontaneous improve-
ment, suggesting that a brief course of observation may be 
appropriate. On the other hand, there is concern that the 
prospects for visual recovery could be irreversibly damaged 
by delaying therapy. Twelve-month data from the BRAVO and 
CRUISE trials suggest that even when sham-treated patients 
were allowed to receive open-label ranibizumab after month 
6, the visual acuity never equaled those of subjects receiving 
ranibizumab from the outset.50
In addition, the relative efficacy of ranibizumab versus 
grid laser for BRVO has not been fully studied. Although 
the magnitude of benefit achieved by ranibizumab-treated 
patients was striking, it is unknown how the BRAVO control 
arm would have fared if these patients were allowed laser 
therapy from the outset. Comparison with the outcomes of 
treated patients in the BVOS study is not advisable, as the 
patient cohorts in the 2 studies may be very different.
While there is preliminary evidence from small pro-
spective studies, CRUISE and BRAVO have not provided 
long-term (beyond one year) data on the efficacy and safety 
of ranibizumab in RVO.43,44 This is of critical importance, 
particularly given the evidence that suggests frequent and 
extended retreatments are likely to be required in patients 
with CRVO.37 The mechanisms underlying this require-
ment are unknown – venous recanalization and/or collateral 
formation is likely to be present after 2 years and, therefore, 
peripheral nonperfusion may play a critical role.37 As such, 
ultra-widefield fluorescein angiography may play a role in 
guiding ranibizumab retreatment and/or modifying therapeu-
tic approach.51 Advances in Doppler OCT technology may 
also allow additional, noninvasive, quantification of retinal 
blood flow in these disorders.52Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Bevacizumab versus ranibizumab
The initial evidence of anti-angiogenic efficacy in the treat-
ment of RVO-associated macular edema was provided by bev-
acizumab.32 A number of off-label, short-term, uncontrolled, 
retrospective case series have since evaluated the efficacy 
of intravitreal bevacizumab in RVO.53,54 The Pan American 
Collaborative Retina Study Group have recently evaluated 
the effects of bevacizumab for both CRVO and BRVO in 
large, retrospective, comparative multi-center studies. For 
CRVO, 56.8% of eyes treated with 1.25 mg of bevacizumab 
gained $3 lines of visual acuity, while 57.1% of eyes treated 
with 2.5 mg of bevacizumab achieved similar gains. In the 
1.25 mg dose group, OCT-derived central retinal thickness 
improved from 635 µm to 264 µm, versus 528 to 293 µm in 
the 2.5 mg dose group. For BRVO, 68% of eyes treated with 
1.25 mg of bevacizumab gained $3 lines of visual   acuity, 
while 72% of eyes treated with 2.5 mg of bevacizumab 
achieved similar gains. In the 1.25 mg dose group, OCT-
derived central retinal thickness improved from 453 µm to 
254 µm, versus 444 to 234 µm in the 2.5 mg dose group.
The use of bevacizumab for the treatment of RVO has 
also been described in a number of small, prospective stud-
ies, although there remains a lack of evidence from random-
ized clinical trials. Prager et al55 have recently described 
the functional and anatomic changes seen in RVO-patients 
treated with bevacizumab (21 BRVO, 8 CRVO). In their 
study, mean visual acuity increased by 16 letters from base-
line to month 12, and central retinal thickness decreased 
from 558 µm at baseline to 309 µm at month 12. Of note, 
fluorescein angiography revealed no progression of avascular 
areas and no drug-related ocular or systemic adverse effects 
were observed. In another prospective study, Figueroa et al56 
evaluated bevacizumab in the treatment of 18 patients with 
CRVO and 28 patients with BRVO. In the BRVO group, mean 
logMAR visual acuity improved from 0.8 ± 0.38 at baseline 
to 0.44 ± 0.34 at 6 months. In the CRVO group, mean log-
MAR visual acuity improved from 1.13 ± 0.21 at baseline 
to 0.83 ± 0.45 at 6 months.
In 2010, the results of ABC (Avastin [Bevacizumab] for 
treatment of Choroidal Neovascularization) trial provided the 
first level I evidence for the efficacy of intravitreal bevaci-
zumab in neovascular AMD.57 Other, ongoing clinical trials, 
such as the CATT (Comparison of Age-Related Macular 
Degeneration Treatments Trials) and IVAN (Inhibit VEGF 
in Age-related choroidal Neovascularization) studies, will 
provide information on the relative efficacy and safety of 
bevacizumab versus ranibizumab in neovascular AMD.58,59 
The results of these studies will likely be of interest for the 
management of RVO, particularly given the low-cost of 
bevacizumab relative to ranibizumab. Doses of ranibizumab 
greater than 0.5 mg (eg, 2.0 mg) are also being evaluated in 
patients with neovascular AMD – such dosages may also be 
of benefit in retinal vascular disease.44,58
Ozurdex
Until recently, the options for treatment of RVO-associated 
macular edema were somewhat limited – now, or in the 
near future, however, clinicians may have the option of 
multiple therapeutic approaches.60 The use of a biode-
gradable   dexamethasone implant (Ozurdex®, Allergan, 
Inc., Irvine, CA), for the treatment of RVO-associated 
macular edema, has recently been approved by the 
FDA (www.ozurdex.com; accessed February 18, 2011). 
In the GENEVA trials of Ozurdex, a single treatment 
with a dexamethasone implant produced significantly 
greater improvements in visual acuity than did a sham 
procedure – the greatest response was at day 60, where 
29% of treated subjects benefited from a 15-letter gain in 
visual acuity, versus 11% in the sham group.61 Just as for 
the SCORE trial, comparison of GENEVA trial results 
with the BRAVO and CRUISE data is challenging because 
of significant differences in the cohorts between the stud-
ies. In the GENEVA trials, among patients with CRVO, 
only 17% of patients had a disease duration of less than 
3 months, compared with 39% in the SCORE-CRVO trial, 
and 69% in the CRUISE study. Given that longer duration 
of disease before treatment negatively impacts the chance 
for visual recovery, this finding complicates assessment of 
the magnitude of treatment efficacy between studies.12,37,60 
Nevertheless, the results of the GENEVA trial highlight the 
main potential benefit of Ozurdex – its extended duration 
of action may allow for less frequent retreatment in RVO-
associated macular edema.
veGF Trap
Another agent, VEGF Trap (Regeneron Pharmaceuticals, 
Tarrytown, NY), is also being evaluated for the treatment 
of RVO-associated macular edema.62 VEGF Trap is a fusion 
protein comprising segments of the extracellular domains 
of human VEGF receptor-1 and VEGF receptor-2, fused to 
the constant region of human immunoglobulin G1. VEGF 
Trap binds to all isoforms of VEGF-A with a higher affinity 
than either bevacizumab or ranibizumab, thereby offering 
a theoretically longer interval between doses. The use of Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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intravitreal “VEGF Trap-Eye” (a formulation of VEGF 
Trap for intraocular delivery) is being evaluated in 2 phase 
III clinical trials: COPERNICUS (Controlled Phase 3 
Evaluation of Repeated intravitreal administration of VEGF 
Trap-Eye in Central retinal vein occlusion) and GALILEO 
(General Assessment Limiting Infiltration of Exudates in 
central retinal vein Occlusion with VEGF Trap-Eye). On 
December 20, 2010, the results of the COPERNICUS study 
were announced. In this trial, 56.1% of patients receiving 
monthly VEGF Trap-Eye (2 mg) gained at least 15 letters 
of visual acuity versus 12.3% of controls. Furthermore, 
the mean change in visual acuity, from baseline, was +17.3 
letters versus −4.0 letters for the sham injection group 
(www.regeneron.com; accessed February 18, 2011).
Choosing among therapies
Because of the differences in patient cohorts and trials 
designs, comparative analyses among the various therapeutic 
trials with respect to safety and efficacy is fraught with com-
plication. In addition, safety and efficacy alone may not be 
the only considerations. Frequency and durability of therapy, 
cost, phakic status, ease of treatment, and comorbid ocular 
and systemic conditions (eg, glaucoma, vascular disease) 
may all factor into the decision-making process. In addi-
tion, the potential benefit and role of combination therapy 
remains unknown (eg, ranibizumab + laser for BRVO). 
It would appear that the best strategy at present would be 
careful and frequent monitoring of all patients, a thorough 
discussion with patients of the available therapies, and selec-
tion of therapy based on the characteristics and needs of the 
individual patient.
Conclusions
The introduction of anti-angiogenic therapies, such as 
ranibizumab, has revolutionized the treatment of neovas-
cular AMD.58 Recent clinical trial evidence suggests that 
such treatments will similarly revolutionize the treatment 
of both BRVO and CRVO.43,44 However, significant gaps 
still remain in our knowledge of ranibizumab applicabil-
ity, and use of ranibizumab is unlikely to be a panacea for 
the treatment of RVO. In the short term, determination of 
optimal retreatment regimens may further improve ranibi-
zumab efficacy, in the longer term, integration with other 
therapeutic approaches may also prove fruitful. Regardless, 
the application of ranibizumab represents an important 
advance in reducing visual debility from RVO-associated 
macular edema.
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